Active Biotech AB Interim report January - September 2012

(Thomson Reuters ONE) -


· Laquinimod - Teva to initiate a new Phase III study in the US at year-end
                   - milestone payment of USD 5 M received following a submitted
application for regulatory approval in Europe
                   - Crohn's Phase II data presented at the UEGW conference

· TASQ        - biomarker data presented at the ESMO conference
                   - Ipsen to initiate two new clinical Phase II studies:
maintenance therapy for prostate cancer and a study of other types of cancer

· ANYARA   - Phase III study results to be presented Q1 2013

· 57-57        - clinical trial of systemic sclerosis/scleroderma is in progress

· ISI            - project proceeding as planned

· Net sales:  SEK 136.4 M (231.3)

· Operating loss: SEK 168.7 M (loss 6.2)

· Loss after tax: SEK 175.1 M (loss: 1.3)

· Loss per share for the period: SEK 2.54 (loss: 0.02)


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

This report is also available at www.activebiotech.com


Active Biotech AB Interim report January - September 2012:
http://hugin.info/1002/R/1656396/535516.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE
[HUG#1656396]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 09.11.2012 - 08:31 Uhr
Sprache: Deutsch
News-ID 201541
Anzahl Zeichen: 2103

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 122 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - September 2012"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech